The global Osteoporosis Drugs Market is growing steadily as the aging population, sedentary lifestyles, and rising fracture risk increase demand for effective bone health treatments. Osteoporosis drugs help prevent bone loss, reduce fracture risk, and improve quality of life for patients with fragile bones.

The global osteoporosis drugs market size was valued at USD 16.43 billion in 2025 and is projected to grow from USD 17.17 billion in 2026 to USD 24.48 billion by 2034, registering a CAGR of 4.53% during the forecast period (2026–2034).

• Market Size (2025): USD 16.43 Billion
• Market Size (2026): USD 17.17 Billion
• CAGR (2026–2034): 4.53%
• Forecast Year: 2034
• Projected Market Size (2034): USD 24.48 Billion
• Dominant Region: North America
• Fastest Growing Region: Europe

Market Overview

Osteoporosis drugs are therapeutic medicines used to treat bone density loss and prevent fractures. Common drug classes include bisphosphonates, selective estrogen receptor modulators, parathyroid hormone therapy, calcitonin, RANK ligand inhibitors, and other advanced therapies.

These drugs are administered through oral and injectable routes depending on patient condition, treatment duration, drug efficacy, and physician recommendation.

Market Growth Drivers

The rising prevalence of osteoporosis is a major factor driving market growth. Osteoporosis affects millions of people globally, especially older adults, and significantly increases the risk of fragility fractures, reduced mobility, and long-term healthcare burden.

The adoption of sedentary lifestyles is also increasing osteoporosis risk. Lack of physical activity, poor bone health, obesity, diabetes, and other lifestyle-related conditions are contributing to higher demand for osteoporosis treatment worldwide.

Market Challenges

Side effects associated with osteoporosis drugs may limit market growth. Bisphosphonates can cause bone, joint, and muscle pain, while oral tablets may lead to nausea, heartburn, swallowing difficulty, esophageal irritation, and gastric ulcers.

Concerns over long-term drug safety and patient reluctance to continue therapy can affect treatment adherence.

Market Opportunities

Emerging markets offer strong growth opportunities. Countries such as China, India, Brazil, and Japan are increasing healthcare spending, improving medical infrastructure, and expanding access to advanced drug delivery systems.

Growing awareness of early diagnosis, rising geriatric populations, and increasing investment by pharmaceutical and biotech companies are expected to support future market expansion.

Segment Analysis

By drug class, the bisphosphonates segment dominates the global market with a 36.80% share. These drugs are widely used as first-line treatments due to their proven ability to reduce bone loss and lower fracture risk.

By route of administration, the oral segment holds the largest market share of 65.60% and is expected to grow steadily. Oral osteoporosis drugs are preferred due to convenience, patient compliance, affordability, and availability of generic options.

Regional Analysis

North America dominates the global osteoporosis drugs market, accounting for more than 38.8% share in 2024. The region benefits from advanced healthcare infrastructure, strong purchasing power, high osteoporosis prevalence, and the presence of major pharmaceutical companies.

Europe is expected to be the fastest-growing region during the forecast period. Rising awareness about early diagnosis, increasing osteoporosis cases, higher disposable income, and the presence of leading companies are supporting regional growth.

Asia-Pacific also offers significant opportunities due to its large population base, rising healthcare expenditure, growing osteoporosis awareness, and increasing access to advanced treatments.

Competitive Landscape

Key companies operating in the global osteoporosis drugs market include:

• Amgen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Radius Health Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Recent Developments

• September 2025: The FDA approved denosumab biosimilars Bildyos and Bilprevda, developed by Shanghai Henlius Biotech and Organon.
• July 2025: mAbxience received European Commission approval for Denbrayce and Izamby for osteoporosis treatment in postmenopausal women and men at high fracture risk.
• July 2025: Celltrion USA launched FDA-approved denosumab biosimilars Stoboclo and Osenvelt in the U.S.
• June 2025: Sandoz launched interchangeable denosumab biosimilars Wyost and Jubbonti in the United States.

Click to Read the Complete Insights & Report:https://straitsresearch.com/report/osteoporosis-drugs-market

Future Outlook

The osteoporosis drugs market is expected to grow steadily as aging populations, fracture prevention needs, and early diagnosis initiatives increase globally. The launch of biosimilars, rising access to affordable therapies, and expanding healthcare infrastructure in emerging economies will continue to shape future market growth.

About Straits Research

Straits Research is a global market intelligence and consulting company that provides industry research, market forecasts, competitive analysis, and strategic insights across diverse sectors. The company helps businesses, investors, and decision-makers understand market trends, identify growth opportunities, and make informed strategic decisions.